亨迪药业公告，股东雷小艳2025.11.18-2026.2.17通过集中竞价减持416.71万股，减持均价14.25元，占公 司总股本0.998%；减持后持股降至1149.29万股，占2.752%，此前为1566万股，占3.75%。本次减持股份 来源均为公司首次公开发行股票前已发行的股份，减持计划已到期并符合相关法规。 ...

湖北亨迪药业股份有限公司 关于股东减持计划时间届满暨减持结果的公告 证券代码：301211 证券简称：亨迪药业 公告编号：2026-004 公司股东雷小艳女士保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 湖北亨迪药业股份有限公司（以下简称"公司"）于 2025 年 11 月 12 日披 露了《关于股东减持股份的预披露公告》（公告编号：2025-050），公司股东雷 小艳女士持有公司股份 15,660,000 股（占公司总股本比例 3.75%），计划在减 持预披露公告披露日起三个交易日后的三个月内以大宗交易方式或集中竞价交 易方式合计减持本公司股份不超过 4,176,000 股（占公司总股本比例 1%）。 公司于近日收到雷小艳女士的《股份减持计划时间届满的告知函》，现将有 关情况公告如下： 一、股东减持情况 1、股东减持股份情况 | 股东名称 | 减持方式 | 减持期间 | 减持均价 | 减持股数 （股） | 减持股数占总 股本比例 | | --- | --- | --- | --- | --- | -- ...

（文章来源：证券日报） 证券日报网讯 2月24日，亨迪药业在互动平台回答投资者提问时表示，截至2026年2月13日，公司股东 户数为20757户。 ...

Product Development Progress - The company announced that its raw material drug, hydrochloride erlotinib, received approval for market application from the National Medical Products Administration on February 3, 2026. This drug is intended for the treatment of non-small cell lung cancer and is expected to enrich the company's product line and enhance market competitiveness [2] Performance and Operating Conditions - On January 20, 2026, the company released its annual performance forecast for 2025, estimating a net profit attributable to shareholders of between 31 million and 39 million yuan, representing a year-on-year decline of 57.40% to 66.14%. The non-recurring net profit is expected to decline by 88.76% to 92.46% year-on-year. The decline in performance is primarily attributed to intensified market competition for ibuprofen raw materials and a decrease in gross profit margin [3] Shareholder Movements - An announcement on November 12, 2025, indicated that three shareholders plan to collectively reduce their holdings in the company by no more than 2.33%. This reduction is scheduled to occur within three months following the announcement, starting 15 trading days after the disclosure. This movement may impact the company's equity structure [4] Financial Situation - Data from January 2026 shows that the company's main funds are in a net inflow state, with a net inflow of 4.9655 million yuan on January 7. This reflects short-term changes in the financial situation and resonates with market sentiment [5]

Group 1 - The core point of the article is that Hendi Pharmaceutical (301211) reported a total of 20,983 shareholders as of February 10, 2026 [1]

Group 1 - Fulin Precision's subsidiary Jiangxi Shenghua invested 270 million yuan to establish a joint venture for a 500,000-ton ferrous oxalate project, with a total investment of 1.5 billion yuan expected to be completed by September 30, 2026 [1] - Xuguang Electronics plans to raise up to 1 billion yuan through a private placement to fund high-voltage vacuum arc extinguishing chamber expansion and other projects [2] - Minexplosion Optoelectronics intends to acquire 100% equity of Xiazhi Precision, with the transaction subject to shareholder and regulatory approvals [3] Group 2 - Shangluo Electronics' controlling shareholder plans to reduce his stake by up to 3% due to personal financial needs [4] - Babi Food reported a 1.3% decline in net profit for 2025, despite an 11.22% increase in revenue [5] - Pengding Holdings' subsidiary acquired industrial land in Huai'an for 66.14 million yuan [6] Group 3 - Zhuoyue New Energy's net profit for 2025 increased by 14.16%, despite a 17.43% decline in revenue [7] - Zhongyuan Media's net profit grew by 30.99% in 2025, with revenue decreasing by 5.13% [8] - Huangshan Tourism plans to invest approximately 530 million yuan in a hotel project with a 24-month construction period [9] Group 4 - *ST Jinling's restructuring plan was approved by the court, which may improve the company's financial situation [11] - Jichuan Pharmaceutical's subsidiary paid 80 million yuan for exclusive commercialization rights of a drug [12] - Pilin Bio's subsidiary received a notice for the acceptance of a drug supplement application [13] Group 5 - Nepe Mining terminated its investment in Swiss Veritas Resources AG due to changes in conditions [14] - Jinhui Wine announced a cash dividend of 0.20 yuan per share for the first three quarters of 2025 [15] - Hualan Biological's clinical trial for a new drug received approval for an additional indication [16] Group 6 - Industrial Fulian reported a total of 247 million yuan spent on share buybacks as of January 31, 2026 [17] - Yitong Century was pre-selected for a 107 million yuan project with China Tower [18] - Wanfeng Co. noted uncertainty in future price changes for disperse dyes [19] Group 7 - Bibet's clinical trial application for a new drug was approved by the National Medical Products Administration [21] - Chengbang Co. signed new project contracts worth 40.03 million yuan in Q4 2025 [22] - *ST Hengji received a court ruling for a performance compensation of 175 million yuan [23] Group 8 - Jihua Group is planning a change in control, leading to continued stock suspension [24] - Ningbo Port expects a container throughput of 5.03 million TEUs in January 2026, a 9.5% increase [25] - Hengli Petrochemical's actual controller increased his stake by 3.3 million shares [26] Group 9 - Hongfuhan signed a sales contract worth 480 million yuan with Guangdong Quanxiang [27] - All New Good's shareholder lifted a judicial freeze on 4.36% of the company's shares [28] - Changchun High-tech's subsidiary's clinical trial application for a new drug was accepted [29] Group 10 - Xingqi Eye Medicine's clinical trial for a new drug entered the first/second phase [31] - Hanma Technology reported a 140.04% increase in new energy heavy truck production in January 2026 [32] - Hengfeng Paper plans to invest 349 million yuan in a new green printing project [33] Group 11 - Zhifei Biological's mRNA vaccine for shingles received clinical trial approval [34] - Yutong Bus reported a 15.35% decrease in production in January 2026 [35] - StarNet Ruijie plans to sign a lease contract with an affiliate for a total rent of up to 110 million yuan [36] Group 12 - Hacheng Bonda's director completed a 0.97% share reduction [37] - Hendi Pharmaceutical's application for a new drug was approved [38] - Xinhua Medical's subsidiary received a medical device registration certificate [40] Group 13 - Yaokang Bio reported a 31.49% increase in net profit for 2025 [41] - Gaotie Electric reported a 14.02% increase in net profit for 2025 [42]

Core Viewpoint - Hendi Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of hydrochloride erlotinib, a targeted drug for treating non-small cell lung cancer [1] Group 1: Company Information - Hendi Pharmaceutical is the developer of hydrochloride erlotinib, an EGFR tyrosine kinase inhibitor [1] - The drug is primarily used for treating locally advanced or metastatic non-small cell lung cancer with sensitive mutations in the EGFR gene [1] Group 2: Industry Context - Hydrochloride erlotinib can also be used for treating advanced non-small cell lung cancer patients who have failed previous chemotherapy [1]

Core Viewpoint - Hendi Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of hydrochloride erlotinib, a targeted drug for treating non-small cell lung cancer [1] Company Summary - Hendi Pharmaceutical (301211.SZ) has recently announced the approval of hydrochloride erlotinib, which is a self-developed EGFR tyrosine kinase inhibitor [1] - The drug is primarily used for treating locally advanced or metastatic non-small cell lung cancer with sensitive mutations in the EGFR gene [1] - It is also indicated for patients with advanced non-small cell lung cancer who have failed previous chemotherapy [1]

Core Viewpoint - Hendi Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of hydrochloride erlotinib, a targeted drug for treating non-small cell lung cancer [1] Group 1: Product Approval - The approval pertains to hydrochloride erlotinib, classified as an EGFR tyrosine kinase inhibitor [1] - This drug is primarily used for treating locally advanced or metastatic non-small cell lung cancer with sensitive mutations in the EGFR gene [1] - It can also be used for patients with advanced non-small cell lung cancer who have failed previous chemotherapy [1]

Core Viewpoint - The company, Hendi Pharmaceutical (301211.SZ), has received approval from the National Medical Products Administration for the marketing application of hydrochloride erlotinib, a targeted drug for treating non-small cell lung cancer [1] Group 1: Product Approval - The National Medical Products Administration has issued a marketing approval notice for hydrochloride erlotinib [1] - Hydrochloride erlotinib is classified as an EGFR tyrosine kinase inhibitor [1] - The drug is primarily used for treating locally advanced or metastatic non-small cell lung cancer with sensitive mutations in the EGFR gene [1] Group 2: Treatment Indications - Hydrochloride erlotinib can also be used for patients with advanced non-small cell lung cancer who have failed previous chemotherapy [1]